Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers

@article{Zucchi2020NeurofilamentsIM,
  title={Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers},
  author={Elisabetta Zucchi and Valentina Bonetto and Gianni Soraru' and Ilaria Martinelli and Piero Parchi and Rocco Liguori and Jessica Mandrioli},
  journal={Molecular Neurodegeneration},
  year={2020},
  volume={15}
}
Motor neuron diseases (MNDs) are etiologically and biologically heterogeneous diseases. The pathobiology of motor neuron degeneration is still largely unknown, and no effective therapy is available. Heterogeneity and lack of specific disease biomarkers have been appointed as leading reasons for past clinical trial failure, and biomarker discovery is pivotal in today’s MND research agenda. In the last decade, neurofilaments (NFs) have emerged as promising biomarkers for the clinical assessment… Expand

Figures from this paper

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
TLDR
The characteristics that make NfL a highly informative biomarker and depict the available technologies used for its measurement are discussed and the growing role of serum and CSF N fL in MS research and clinical settings is discussed. Expand
Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study
TLDR
The stable longitudinal trajectory of pNfL supports its use as a marker of drug effect in clinical trials and has excellent diagnostic and prognostic performance for symptomatic patients with ALS. Expand
Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion
TLDR
A conceptual framework is provided for assessing the putative involvement of C9orf72 as a synaptopathy focusing on integrating mitochondrial and neuronal cytoskeleton degeneration as biomarkers and potential targets to treat ALS neurodegeneration. Expand
Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?
TLDR
An up-to-date state of the art of neuropsychological alterations in ALS is sought, tests used to detect cognitive and behavioral impairment are described, and promising non-invasive biomarkers to detect pre-clinical cognitive decline are focused on. Expand
CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement
Objective: To assess whether phosphorylated neurofilament heavy chain (pNfH) can discriminate different upper motor neuron (UMN) syndromes, namely, ALS, UMN-predominant ALS, primary lateral sclerosisExpand
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS
TLDR
It is demonstrated that CSF NfL and NfH as well as serum NFL are equally suited for the differential diagnosis of ALS, whereas serum N fH appears to be slightly less potent. Expand
Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction
TLDR
It can be summarized that there is neuropathological evidence that protein aggregates of AD and PD are present both at the soma and the synapse, and a number of CSF and PET biomarkers beyond α-synuclein, tau and Aβ might capture these different faces of protein-related neurodegeneration. Expand
Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD–ALS spectrum
TLDR
NfL, but not pNfH, appeared to be useful in a context of differential diagnosis between FTD and psychiatric patients, Nevertheless, pNFH seem more specific for the diagnosis and follow-up of motor impairments. Expand
Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson’s Disease: Roads to Biomarker Discovery
TLDR
The main pathways involved in PD pathogenesis are illustrated and their possible exploitation for biomarker discovery is discussed. Expand
New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis
TLDR
Known contributors, including variants in genetic loci and aberrant protein activities, which modify cytoskeletal integrity, axonal transport and mitochondrial localization in ALS and have overlapping features with other neurodegenerative diseases are reviewed. Expand
...
1
2
...

References

SHOWING 1-10 OF 125 REFERENCES
Neurofilament light chain as a biomarker in neurological disorders
TLDR
Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and N fL is one of the most promising biomarkers to be used in clinical and research setting in the next future. Expand
Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis
TLDR
Among all biomarkers, NfL yielded the highest diagnostic performance and was the best predictor of disease progression rate and survival in ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes. Expand
Neurofilaments as biomarkers in neurological disorders
TLDR
How technological advances have enabled the detection of neurofilament proteins in the blood is considered, and how these proteins consequently have the potential to be easily measured biomarkers of neuroaxonal injury in various neurological conditions are discussed. Expand
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
TLDR
Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients and their value as prognostic markers should be investigated further. Expand
CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis
TLDR
It is confirmed that CSF NF-L and pNF-H represent valuable diagnostic and prognostic biomarkers in ALS and were significantly increased when compared to CTL-1. Expand
Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis
TLDR
NF heavy and light chain levels have potential use as a marker of neural degeneration in ALS, but are not specific for the disease, and are more likely to be used as measures of disease progression. Expand
Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival
TLDR
The notion of CSF NFL as a useful tool for determining disease intensity in MND and FTD patients is strengthened and further studies in patient cohorts with clinically subtyped and genetically classified diagnoses are needed. Expand
Biomarkers in Motor Neuron Disease: A State of the Art Review
TLDR
This review highlights biomarkers that have emerged from the fields of systemic measurements including biochemistry (blood, cerebrospinal fluid, and urine analysis); imaging and electrophysiology, and gives examples of how a combinatorial approach may yield the best results. Expand
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
TLDR
The data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a possible surrogate to quantify effects of neuroprotective drugs in clinical trials. Expand
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
TLDR
Serum NfL may be considered a clinically validated prognostic biomarker for ALS and has potential utility as a pharmacodynamic biomarker of treatment effect, depending on the method used to estimate effect size. Expand
...
1
2
3
4
5
...